Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag dna-damage-response

Unveiling Potential: Exploring Alpha Emitter Radiopharmaceuticals

XTalks

JANUARY 19, 2024

The aim of these compounds is to deliver radiation directly to the tumor cells, minimizing damage to surrounding healthy tissues. Recent evidence has shown the impressive safety and tumor responses of alpha particle therapy across various solid tumors. Alpha particles are helium nuclei consisting of two protons and two neutrons.

DNA

DNA Radiology FDA Approval Development

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Delveinsight

DECEMBER 3, 2020

AMD Patients often have low levels of CD59, which is a protein that protects the retina from damage caused by a vital part of the body’s natural immune response called complement. An overactivity of complement damages cells in the macula in geographic atrophy. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy

Gene Therapy Gene Antibody Research

Unveiling Potential: Exploring Alpha Emitter Radiopharmaceuticals

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Stay Connected